RWD80 Gastrointestinal Adverse Events in Lung Cancer Patients Treated with Ipilimumab and Nivolumab Using Real-World Data

Abstract

Evidence shows that programmed death receptor-1 (PD-1)-blocking and human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibodies display apparent benefits in lung cancer therapy. Further, lung cancer patients who receive nivolumab (PD-1 inhibitor) plus ipilimumab (CLTA-4 inhibitor) in combination have higher overall survival rate than those treated with ipilimumab alone. However, adverse events (AE) are still a concern, especially gastrointestinal (GI) AEs. Since GI AE is one of the most common reasons for patients stopping immunotherapy, we utilized real-world data to gain insight in the incidence and severity of GI AEs among lung cancer patients treated with nivolumab and ipilimumab.